Identification of an upstream promoter of the human somatostatin receptor, hSSTR2, which is controlled by epigenetic modifications

Endocrinology

Volumn 149, Issue 6, 2008, Pages 3137-3147

  Torrisani, Jérôme ^a   Hanoun, Naïma ^a   Laurell, Henrik ^a   Lopez, Frédéric ^b   Maoret, Jean José ^b   Souque, Anny ^a   Susini, Christiane ^a   Cordelier, Pierre ^a   Buscail, Louis ^a,b,c  

^a INSERM   (France)

^b CHU RANGUEIL   (France)

^c et Signalisation 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; GENOMIC DNA; HISTONE; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; SOMATOSTATIN RECEPTOR 2; TRANSCRIPTION FACTOR SP1; TRICHOSTATIN A;

ACETYLATION; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA MODIFICATION; DNA SEQUENCE; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN MODIFICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION SITE;

BASE SEQUENCE; CHROMATIN; CHROMOSOMES, HUMAN, PAIR 17; DINUCLEOSIDE PHOSPHATES; DNA METHYLATION; EXONS; GENES, REPORTER; HUMANS; LUCIFERASES; MOLECULAR SEQUENCE DATA; PLASMIDS; PROMOTER REGIONS (GENETICS); RECEPTORS, SOMATOSTATIN; RNA, MESSENGER; SEQUENCE DELETION; SEQUENCE HOMOLOGY, NUCLEIC ACID;

EID: 44349090960     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2007-1525     Document Type: Article

References (46)

1. Guillermet-Guibert J, Lahlou H, Cordelier P, Bousquet C, Pyronnet S, Susini C 2005 Physiology of somatostatin receptors. J Endocrinol Invest 28:5-9
2. Gillies G 1997 Somatostatin: the neuroendocrine story. Trends Pharmacol Sci 18:87-95
3. Susini C, Buscail L 2006 Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 17:1733-1742
4. Kvols LK, Woltering EA 2006 Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors. Anticancer Drugs 17:601-608
5. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB 1995 The somatostatin receptor family. Life Sci 57:1249-1265
6. Lopez F, Esteve JP, Buscail L, Delesque N, Saint-Laurent N, Vaysse N, Susini C 1996 Molecular mechanisms of antiproliferative effect of somatostatin: involvement of a tyrosine phosphatase. Metabolism 45:14-16
7. Buscail L, Esteve JP, Saint-Laurent N, Bertrand V, Reisine T, O'Carroll AM, Bell GI, Schally AV, Vaysse N, Susini C 1995 Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci USA 92:1580-1584
8. Guillermet-Guibert J, Saint-Laurent N, Davenne L, Rochaix P, Cuvillier O, Culler MD, Pradayrol L, Buscail L, Susini C, Bousquet C 2007 Novel synergistic mechanism for sst2 somatostatin and TNFα receptors to induce apoptosis: crosstalk between NF-γB and JNK pathways. Cell Death Differ 14:197-208
9. Greenwood MT, Robertson LA, Patel YC 1995 Cloning of the gene encoding human somatostatin receptor 2: sequence analysis of the 5′-flanking promoter region. Gene 159:291-292
10. Li M, Li W, Kim HJ, Yao Q, Chen C, Fisher WE 2004 Characterization of somatostatin receptor expression in human pancreatic cancer using real-time RT-PCR. J Surg Res 119:130-137
11. Buscail L, Saint-Laurent N, Chastre E, Vaillant JC, Gespach C, Capella G, Kalthoff H, Lluis F, Vaysse N, Susini C 1996 Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res 56:1823-1827
12. Fisher WE, Wu Y, Amaya F, Berger DH 2002 Somatostatin receptor subtype 2 gene therapy inhibits pancreatic cancer in vitro. J Surg Res 105:58-64
13. Reubi JC, Horisberger U, Essed CE, Jeekel J, Klijn JG, Lamberts SW 1988 Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas. Gastroenterology 95:760-763
14. Petersenn S, Rasch AC, Presch S, Beil FU, Schulte HM 1999 Genomic structure and transcriptional regulation of the human somatostatin receptor type 2. Mol Cell Endocrinol 157:75-85
15. Pscherer A, Dorflinger U, Kirfel J, Gawlas K, Ruschoff J, Buettner R, Schule R 1996 The helix-loop-helix transcription factor SEF-2 regulates the activity of a novel initiator element in the promoter of the human somatostatin receptor II gene. EMBO J 15:6680-6690
16. Xu Y, Berelowitz M, Bruno JF 1998 Characterization of the promoter region of the human somatostatin receptor subtype 2 gene and localization of sequences required for estrogen-responsiveness. Mol Cell Endocrinol 139:71-77
17. Patel YC, Greenwood M, Kent G, Panetta R, Srikant CB 1993 Multiple gene transcripts of the somatostatin receptor SSTR2: tissue selective distribution and cAMP regulation. Biochem Biophys Res Commun 192:288-294
18. Kraus J, Woltje M, Schonwetter N, Hollt V 1998 Alternative promoter usage and tissue specific expression of the mouse somatostatin receptor 2 gene. FEBS Lett 428:165-170
19. Petersenn S, Rasch AC, Bohnke C, Schulte HM 2002 Identification of an upstream pituitary-active promoter of human somatostatin receptor subtype 5. Endocrinology 143:2626-2634
20. Gardiner-Garden M, Frommer M 1987 CpG islands in vertebrate genomes. J Mol Biol 196:261-282
21. Bestor TH 2000 The DNA methyltransferases of mammals. Hum Mol Genet 9:2395-2402
22. Bird AP 1980 DNA methylation and the frequency of CpG in animal DNA. Nucleic Acids Res 8:1499-1504
23. Riggs AD, Pfeifer GP 1992 X-chromosome inactivation and cell memory. Trends Genet 8:169-174
24. Razin A, Cedar H 1994 DNA methylation and genomic imprinting. Cell 77:473-476
25. Bird AP 1996 The relationship of DNA methylation to cancer. Cancer Surv 28:87-101
26. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A 1998 Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393:386-389
27. Li L, He S, Sun JM, Davie JR 2004 Gene regulation by Sp1 and Sp3. Biochem Cell Biol 82:460-471
28. Zhu WG, Srinivasan K, Dai Z, Duan W, Druhan LJ, Ding H, Yee L, Villalona-Calero MA, Plass C, Otterson GA 2003 Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter. Mol Cell Biol 23:4056-4065
29. Corpet F 1988 Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res 16:10881-10890
30. Vezzosi D, Bouisson M, Escourrou G, Laurell H, Selves J, Seguin P, Pradayrol L, Caron P, Buscail L 2006 Clinical utility of telomerase for the diagnosis of malignant well-differentiated endocrine tumours. Clin Endocrinol (Oxf) 64:63-67
31. Torrisani J, Unterberger A, Tendulkar SR, Shikimi K, Szyf M 2007 AUF1 cell cycle variations define genomic DNA methylation by regulation of DNMT1 mRNA stability. Mol Cell Biol 27:395-410
32. Ogbourne S, Antalis TM 1998 Transcriptional control and the role of silencers in transcriptional regulation in eukaryotes. Biochem J 331(Pt 1):1-14
33. Kimura N, Tomizawa S, Arai KN, Osamura RY, Kimura N 2001 Characterization of 5′-flanking region of rat somatostatin receptor sst2 gene: transcriptional regulatory elements and activation by Pitx1 and estrogen. Endocrinology 142:1427-1441
34. Klisovic DD, O'Dorisio MS, Katz SE, Sall JW, Balster D, O'Dorisio TM, Craig E, Lubow M 2001 Somatostatin receptor gene expression in human ocular tissues: RT-PCR and immunohistochemical study. Invest Ophthalmol Vis Sci 42:2193-2201
35. Orlando C, Raggi CC, Bianchi S, Distante V, Simi L, Vezzosi V, Gelmini S, Pinzani P, Smith MC, Buonamano A, Lazzeri E, Pazzagli M, Cataliotti L, Maggi M, Serio M 2004 Measurement of somatostatin receptor subtype 2 mRNA in breast cancer and corresponding normal tissue. Endocr Relat Cancer 11:323-332
36. de Herder WW, Hofland LJ, van der Lely AJ, Lamberts SW 2003 Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer 10:451-458
37. Puente E, Saint-Laurent N, Torrisani J, Furet C, Schally AV, Vaysse N, Buscail L, Susini C 2001 Transcriptional activation of mouse sst2 somatostatin receptor promoter by transforming growth factor-β. Involvement of Smad4. J Biol Chem 276:13461-13468
38. Archey WB, Sweet MP, Alig GC, Arrick BA 1999 Methylation of CpGs as a determinant of transcriptional activation at alternative promoters for transforming growth factor-β3. Cancer Res 59:2292-2296
39. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP 2000 Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25:315-319
40. Shmelkov SV, Jun L, St Clair R, McGarrigle D, Derderian CA, Usenko JK, Costa C, Zhang F, Guo X, Rafii S 2004 Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. Blood 103:2055-2061
41. Kimura N, Takamatsu N, Yaoita Y, Osamura RY, Kimura N 2008 Identification of transcriptional regulatory elements in the human somatostatin receptor sst2 promoter and regions including estrogen response element half-site for estrogen activation. J Mol Endocrinol 40:75-91
42. Gahr S, Ocker M, Ganslmayer M, Zopf S, Okamoto K, Hartl A, Leitner S, Hahn EG, Herold C 2007 The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells. Int J Oncol 31:567-576
43. Abele R, Clavel M, Dodion P, Bruntsch U, Gundersen S, Smyth J, Renard J, van Glabbeke M, Pinedo HM 1987 The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. Eur J Cancer Clin Oncol 23:1921-1924
44. Santini V, Kantarjian HM, Issa JP 2001 Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 134:573-586
45. Vernejoul F, Ghenassia L, Souque A, Lulka H, Drocourt D, Cordelier P, Pradayrol L, Pyronnet S, Buscail L, Tiraby G 2006 Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth. Mol Ther 14:758-767
46. Momparler RL, Derse D 1979 Kinetics of phosphorylation of 5-aza-2′-deoxycytidine by deoxycytidine kinase. Biochem Pharmacol 28:1443-1444